Enphase Energy Inc vs Nuwellis Inc — how do they compare? Enphase Energy Inc trades at $33.24 (market cap $4.43B), while Nuwellis Inc trades at $0.68 (market cap $2.20M). The key difference: Enphase Energy Inc is far larger — about 2013.6× Nuwellis Inc's market cap, and Enphase Energy Inc is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enphase Energy Inc for 72 Days and Nuwellis Inc for 26 Days on average.
| ENPH | NUWE | |
|---|---|---|
Market Cap | $4.43B | $2.20M |
Volume | 3,388,482 | 121,544 |
Sector | Energy | Health |
52-Week High | $72.33 | $146.65 |
52-Week Low | $26.12 | $0.68 |
Typical Hold Time | 72 Days | 26 Days |
Enterprise Value | $4.07B | -$1.52M |
Signals from Pluang's Aura AI — not financial advice
ENPH trades at $33.50, down 1.21% on the day, with a bearish technical signal and mixed earnings history. Revenue declined to $1.47B in 2025 from $2.3B in 2023, though net income margin improved to 11.68%. Recent news includes product approvals and manufacturing milestones for AI data centers, but the stock faces pressure from high borrowing costs impacting the solar sector. The company maintains solid liquidity with $1.62B in cash, but debt levels remain elevated.
The outlook is cautious; analyst consensus is a Buy with a $42.90 price target, but recent earnings misses and sector headwinds pose risks. Upside depends on execution in AI infrastructure and EV charging, while competition and interest rate sensitivity are key concerns. The stock offers potential for recovery if operational trends stabilize.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.
Read more on ENPH →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →